Showing results (141-150 of 163) with videos related to

Sort By:
Pageof 17
Lung Cancer (Amsterdam, Netherlands)|May 18, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)Francesco Facchinetti, Andrea Camerini, Chiara Bennati, et al.
Lung Cancer (Amsterdam, Netherlands)|December 29, 2023
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access programFrancesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLCFederica Pecci, Hui Li, Alessandro Di Federico, et al.
Clinical Lung Cancer|March 20, 2019
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC PatientsAlessio Cortellini, Rita Chiari, Biagio Ricciuti, et al.
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
JTO Clinical and Research Reports|February 16, 2023
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC RegistryGiannis Mountzios, David Planchard, Giulio Metro, et al.
Nature Medicine|September 30, 2025
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trialPaolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2025
The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome TrialAndrea Botticelli, Chiara Cremolini, Simone Scagnoli, et al.
Cancer Treatment and Research Communications|February 18, 2026
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trialChiara Mattioli, Emanuela Olmetto, Marco Banini, et al.
Pageof 17